The average prediction of analysts places 'Revenus- Network solutions' at $26.04 million. The estimate indicates a change of +20% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenus- Payment processing fees' of $27.92 million. The estimate indicates a change of +15.1% from the prior-year quarter. Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.51 per share in its upcoming report, which indicates a year-over-year increase of 27.1%. Revenu ...

andreswd Summary Following my coverage of Phreesia (NYSE:PHR), for which I reiterated a buy rating given that fundamentals remained sound and that PHR could continue to see pricing tailwinds ahead, this post is to provide an update on my thoughts on the business and stock. I reiterate my buy rating for PHR as I see the business continuing to grow revenue at 20+% and the adjusted EBITDA margin inflecting upwards as the business scales. The new product rolled out to target post-script engagements should also ...

Phreesia (PHR) reported $95.01 million in revenue for the quarter ended January 2024, representing a year-over-year increase of 24%. EPS of -$0.56 for the same period compares to -$0.72 a year ago.The reported revenue represents a surprise of +2.01% over the Zacks Consensus Estimate of $93.13 million. With the consensus EPS estimate being -$0.58, the EPS surprise was +3.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Phreesia (PHR) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1521 Concord Pike, Suite 301 PMB 221 Wilmington, DE (Address of Principal Executive Offices) (Zip Code) 1 (888) 654-7473 (Registrant's Telephone Number, Including Area Code) For the fiscal year ended January 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...

Exhibit 99.1 Phreesia Announces Fourth Quarter Fiscal 2024 Results WILMINGTON, Delaware, March 14, 2024 – Phreesia, Inc. (NYSE: PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2024. "Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025. We facilitated more than 150 million patient visits in fiscal 2024, or more than one in ten patient visits across the U.S. We are confident that our solutions and our ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Phreesia (PHR) reports results for the quarter ended January 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on March 14, 2024, might help the stock move higher if these key numbers are better than expecta ...

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia is proud to announce that its Chief Clinical Officer Hilary Hatch, PhD, has been selected to participate in the National Quality Forum (NQF)’s 2024-2025 Leadership Consortium. Dr. Hatch is one of only 29 healthcare leaders included in the prestigious group, underscoring her dedication to healthcare quality and patient-centered care. She was first named to the group for a two-year term in 2022. NQF’s Leadership Consortium is an exclusive forum of experts represent ...

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, is proud to release data from an analysis of its cancer prevention campaigns illustrating the significant impact its platform can have on increasing rates of cancer screenings. By engaging patients at critical moments in their healthcare journey, Phreesia is driving an effort to ensure that cancer is caught early, at a stage when it can be treated with good health outcomes. The analysis revealed that when pati ...

Phreesia (PHR) is a Zacks Rank #1 (Strong Buy) that has a F for Value and B for Growth.  This is medical information systems company is flying under the radar of most investors as it is a small cap and currently losing money.  The thing is, the company recently accelerated it push to profitability.  Let’s explore more about this company in this Bull of The Day article.DescriptionPhreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinica ...